Zolbetuximab Plus mFOLFOX for CLDN18.2+/HER2- Advanced Gastric/GEJ Cancers
Samuel Klempner, MD, explains the rationale for the phase 3 SPOTLIGHT study.
Fitting Zolbetuximab into the Gastric/GEJ Cancer Treatment Paradigm
Samuel Klempner, MD, discusses zolbetuximab for patients with claudin 18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction cancer.
DKK1-Targeted Agent Shows Efficacy in Gastroesophageal Cancer
Samuel J. Klempner, MD, discusses the preliminary results of a study of the investigational agent DKN-01 for patients with gastroesophageal adenocarcinoma.
Mechanism of Action of DKN-01 in Gastroesophageal Adenocarcinoma
Samuel J. Klempner, MD, discusses the mechanism of action of the investigational agent DKN-01 in patients with gastroesophageal adenocarcinoma.
Unmet Needs For Targeted Therapies in Gastroesophageal Adenocarcinoma
Samuel J. Klempner, MD, discusses unmet needs in patients with gastroesophageal adenocarcinoma when it comes to biomarker-targeted agents.